Institute of Medicine report called the pattern of higher rates of disease and shorter lives “the U.S. health disadvantage,” and said it was responsible for dragging the country to the bottom in terms of life expectancy over the past 30 years.
“Unfortunately, the entire evidence base has been perverted,” said Joseph Ross, a professor at Yale Medical School who has studied the issue.
“You could say these marketing tactics are merely concerning. But I think of them as satanic. What the data are telling us is that these drugs are ruining people’s lives,” said Phillip Prior, MD
"I’m as big a fan of the 1st Amendment as anyone, but this decision strikes me as fundamentally flawed. We’re not talking about a right to express yourself. We’re talking about selling stuff — stuff that could harm or even kill you if used improperly." David Lazarus, LA Times
Physicians at Sloan Kettering Cancer Center have taken a giant step toward stemming the tide of unconscionable pharmaceutical industry price gouging. Sloan-Kettering physicians said NO to Sanofi’s new anti-cancer drug, Zaltrap which the company priced at $11,063 per month. Drs. Peter B. Bach, Leonard B. Saltz, and Robert E Wittes…
Part II. What Do We Get for All That Money? A preventable epidemic of injury and death from prescription drugs; FDA’s contribution to the epidemic; Big Pharma’s business model: manufactured myths, propaganda and a hidden agenda;
Part I. America’s commercially profitable healthcare system is wasteful, inefficient and exceedingly harmful. Medical interventions are the third Leading cause of death.
The latest area of controversy focuses on the proposed revision of the definition "behavioral addiction disorder" extending the addiction diagnosis to include drug, alcohol and gambling. It is estimated that the change would expand the number of people labeled as "addicts" by 20 to 30 million who would be entitled to treatment and disability payments costing taxpayers many hundreds of millions of dollars.
Healthcare providers and insurers, in the pursuit of increased profits, have resorted to ruthless tactics befitting Mafia enforcers or loan sharks, when interfacing with patients.
On Friday, April 6, the FDA approved another of Eli Lilly’s "breakthroughs" whose clinical value is questionable (at best).
“Overuse is one of the most serious crises in American medicine.” The crisis is not only of misspending of resources, overuse of medical treatments is causing treatment-produced harm, including preventable deaths.
An audit by Daniel Levinson, Inspector General of DHHS, confirms what has already been documented: that antipsychotics are widely misprescribed for unapproved uses and taxpayers are saddled with the high cost through Medicaid and Medicare.
